trending Market Intelligence /marketintelligence/en/news-insights/trending/UG41_qpS0fsdGSWx6tsJIQ2 content esgSubNav
In This List

Allakos prices upsized $350M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allakos prices upsized $350M common stock offering

Allakos Inc. priced its upsized offering of 4,545,454 common shares at $77 per share.

The Redwood City, Calif.-based drugmaker also granted underwriters an option to buy up to an additional $52.5 million worth of shares.

The offering size of $350 million was upsized from a previous offering size of $200 million.

Allakos, which develops therapies targeting allergic, inflammatory and proliferative diseases, plans to use net proceeds for general corporate purposes.

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering, while William Blair & Co. LLC and LifeSci Capital LLC are acting as the co-managers.